Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Karen N Price
Design, Conduct, and Analyses of Breast International Group (BIG) 1-98: A Randomized, Double-Blind, Phase-Iii Study Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor-Positive, Early Breast Cancer
Clinical Trials
Medicine
Pharmacology
Related publications
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Cognitive Function in Postmenopausal Breast Cancer Patients One Year After Completing Adjuvant Endocrine Therapy With Letrozole and/or Tamoxifen in the BIG 1-98 Trial
Breast Cancer Research and Treatment
Cancer Research
Oncology
Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer
Breast Care
Surgery
Oncology
Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Low P27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy
Clinical Cancer Research
Cancer Research
Oncology
Adjuvant Endocrine Monotherapy for Postmenopausal Early Breast Cancer Patients With Hormone-Receptor Positive: A Systemic Review and Network Meta-Analysis
Breast Cancer
Nuclear Medicine
Radiology
Pharmacology
Oncology
Imaging
Medicine
Efficacy of First-Line Letrozole Versus Tamoxifen as a Function of Age in Postmenopausal Women With Advanced Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer
JAMA Oncology
Cancer Research
Oncology
MiR-4653-3p and Its Target Gene FRS2 Are Prognostic Biomarkers for Hormone Receptor Positive Breast Cancer Patients Receiving Tamoxifen as Adjuvant Endocrine Therapy
Oncotarget
Oncology
